Yahoo Finance • 10 days ago
Results from OVATION 2 Study reinforce IMNN-001 efficacy benefits observed in the clinic and unique mechanism of action, producing key anti-cancer immune cytokines post-treatment Pivotal Phase 3 trial of IMNN-001 underway, with four trial... Full story
Yahoo Finance • 13 days ago
OVATION 3 pivotal Phase 3 trial is currently advancing IMNN-001, with several patients being treated LAWRENCEVILLE, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development wi... Full story
Yahoo Finance • 30 days ago
LAWRENCEVILLE, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development with its DNA-mediated immunotherapy, today announced that a pre-recorded presentation from the Company w... Full story
Yahoo Finance • last month
* IMUNON (NASDAQ:IMNN [https://seekingalpha.com/symbol/IMNN]) on Thursday said it has regained compliance with the minimum bid price requirement for continued listing on Nasdaq. * As a result, IMUNON common stock will continue uninterr... Full story
Yahoo Finance • last month
LAWRENCEVILLE, N.J., Aug. 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that the Company has regained compliance with the mini... Full story
Yahoo Finance • 2 months ago
IMUNON INC (NASDAQ:IMNN [https://www.chartmill.com/stock/quote/IMNN]) reported its second-quarter 2025 financial results, revealing a mixed reaction from the market despite beating analyst expectations on earnings per share (EPS). The comp... Full story
Yahoo Finance • 2 months ago
Stock dividend issued to IMUNON shareholders reflects confidence in clinical programs, long-term growth strategy and dedication to rewarding shareholders First patient dosed in Phase 3 OVATION 3 Study of IMNN-001 for treatment of newly di... Full story
Yahoo Finance • 2 months ago
Initiation of additional trial sites and patient enrollment activities ongoing with multiple patients in screening LAWRENCEVILLE, N.J., July 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 d... Full story
Yahoo Finance • 2 months ago
LAWRENCEVILLE, N.J., July 29, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in late-stage development with its DNA-mediated immunotherapy, announces that the Company will host a conference call at 11:00 a... Full story
Yahoo Finance • 2 months ago
* Imunon (NASDAQ:IMNN [https://seekingalpha.com/symbol/IMNN]) declares $0.15/share dividend [https://seekingalpha.com/pr/20179224-imunon-announces-stock-dividend-boosting-shareholder-value]. * Payable Aug. 21; for shareholders of reco... Full story
Yahoo Finance • 2 months ago
Stock Dividend Reflects Company’s Confidence in its Phase 3 Study, Long-term Growth Potential, and Dedication to Shareholders LAWRENCEVILLE, N.J., July 28, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company i... Full story
Yahoo Finance • 3 months ago
Management provides Nasdaq Hearing Panel with a comprehensive executable plan for long term compliance LAWRENCEVILLE, N.J., July 15, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage company in Phase 3 development o... Full story
Yahoo Finance • 3 months ago
Imunon, Inc. (NASDAQ:IMNN), currently trading at $0.52 and with a market capitalization of $11 million, announced Monday that it has been granted an exception by a Nasdaq Hearing Panel to address its non-compliance with continued listing s... Full story
Yahoo Finance • 3 months ago
Imunon, Inc. LAWRENCEVILLE, N.J., June 30, 2025 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ: IMNN), a clinical-stage company in Phase 3 development of its DNA-mediated immunotherapy, today announced that, in consultation with The Nasdaq Stoc... Full story
Yahoo Finance • 3 months ago
ASCO 2025 overall survival data bolster IMNN-001’s potential in advanced ovarian cancer, supported by robust translational results at ESMO Results from OVATION 2 Study reinforce IMNN-001 mechanism of action, producing IL-12 and key anti-c... Full story
Yahoo Finance • 4 months ago
Clinical Data Highlight PlaCCine’s Six-Month Durability, Temperature Stability, and Manufacturing Advantages Over mRNA Vaccines IMUNON Seeks Strategic Partner for PlaCCine® to Advance Novel Technology and Fund Core Pipeline with Non-Dilut... Full story
Yahoo Finance • 4 months ago
NEW YORK, June 13, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Life Sciences Investor Forum, held June 11th and 12th are now availa... Full story
Yahoo Finance • 4 months ago
NEW YORK, June 10, 2025 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series announced the agenda for the Life Sciences Investor Forum June 11th & 12th. This event is co-hosted by Zacks Sma... Full story
Yahoo Finance • 4 months ago
Consistent OS Efficacy Benefit Across Multiple Treatment Subgroups Demonstrates IMNN-001’s Ability to Recruit a Powerful Anti-Cancer Immune Response Results, presented simultaneously in oral presentation at ASCO 2025 and in peer-reviewed... Full story
Yahoo Finance • 4 months ago
Outstanding Phase 2 Results will be discussed at the 2025 ASCO in an Oral Presentation and featured in peer reviewed medical journal Gynecologic Oncology Phase 3 OVATION 3 Study in progress LAWRENCEVILLE, N.J. , June 02, 2025 (GLOBE NE... Full story